Doxorubicin-loaded PLGA Microparticles with Internal Pores for Longacting Release in Pulmonary Tumor Inhalation Treatment  

作　　者：Tian-shi Feng 田华雨 Cai-na Xu Lin Lin Michael Hon-Wah Lam Hao-jun Liang Xue-si Chen 

机构地区：[1]CAS Key Laboratory of Soft Matter Chemistry,Department of Polymer Science and Engineering,University of Science and Technology of China [2]Key Laboratory of Polymer Ecomaterials,Changchun Institute of Applied Chemistry,Chinese Academy of Sciences [3]Department of Biology and Chemistry,City University of Hong Kong [4]Advanced Laboratory of Environmental Research and Technology(ALERT),Joint Advanced Research Center

出　　处：《Chinese Journal of Polymer Science》2015年第7期947-954,共8页高分子科学（英文版）

基　　金：financially supported by the National Natural Science Foundation of China(Nos.51222307,51303173,51390480,21474104 and 51403205);the Ministry of Science and Technology of China(International cooperation and communication program 2011DFR51090);Jilin Province Science and Technology Development Program(Nos.20120306,20130521011JH)

摘　　要：Doxorubicin（DOX） loaded poly（lactic-co-glycolic acid）（PLGA） microparticles with internal pores（MP-D） were developed for long-acting release in pulmonary inhalation treatment. The PLGA microparticles exhibited favorable aerodynamic properties for pulmonary delivery. In vitro drug release profile suggested that MP-D have the advantage of long-term maintenance of drug concentrations. MTT assay demonstrated the in vitro anti-tumor efficiency of the DOX loaded PLGA microparticles. Furthermore, melanoma lung metastasis model was established to determine the in vivo antitumor efficiency. The mice treated with MP-D showed significantly fewer lesions than the untreated ones. The survival analysis indicated that MP-D prolonged the survival time of tumor-bearing mice. These results suggested that DOX loaded PLGA microparticles with internal pores have the potential to be used as long-acting release carriers in clinical lung cancer treatment.Doxorubicin（DOX） loaded poly（lactic-co-glycolic acid）（PLGA） microparticles with internal pores（MP-D） were developed for long-acting release in pulmonary inhalation treatment. The PLGA microparticles exhibited favorable aerodynamic properties for pulmonary delivery. In vitro drug release profile suggested that MP-D have the advantage of long-term maintenance of drug concentrations. MTT assay demonstrated the in vitro anti-tumor efficiency of the DOX loaded PLGA microparticles. Furthermore, melanoma lung metastasis model was established to determine the in vivo antitumor efficiency. The mice treated with MP-D showed significantly fewer lesions than the untreated ones. The survival analysis indicated that MP-D prolonged the survival time of tumor-bearing mice. These results suggested that DOX loaded PLGA microparticles with internal pores have the potential to be used as long-acting release carriers in clinical lung cancer treatment.

关 键 词：Doxorubicin Poly（lactic-co-glycolic acid） Internal pores Long-acting release Pulmonary inhalation 

分 类 号：R734.2[医药卫生—肿瘤]